Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study reveals key factors in 90-Day survival for advanced cancer patients after ER

NCT ID NCT07167095

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study reviewed medical records of 1,250 advanced cancer patients who visited the emergency department. Researchers looked at factors like age, tumor type, and blood test results to see which patients were at higher risk of dying within 90 days. The goal is to help doctors better triage and refer patients to supportive care after an ER visit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which advanced cancer patients need extra support or palliative care after an ER visit, potentially improving their quality of life.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient care. The findings may not apply to other hospitals or countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,250 people

The number who actually took part.

Started

Dec 2022

Finished

Mar 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (aged 18 years and older) with stage IV solid tumors who presented to the emergency department of Etlik City Hospital (Ankara, Türkiye) between December 2022 and March 2025. Eligible patients must have received systemic anticancer therapy within the preceding 6 months. Both patients discharged from the ED and those who were hospitalized or who died during their ED visit are included. The estimated enrollment is 1,250 patients.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Pathologically confirmed stage IV (metastatic) solid malignancy * Followed at Etlik City Hospital, Department of Medical Oncology * Presented to the emergency department between December 2022 and March 2025 * Either discharged on the same day, admitted to the hospital, or died during the ED visit * Received systemic anticancer therapy (chemotherapy, immunotherapy, targeted therapy, or hormonal therapy) within the past 6 months * Availability of complete clinical and laboratory data Exclusion Criteria: * Stage I-III cancer patients * Patients not receiving systemic therapy, only palliative/supportive care * Patients followed in other oncology centers but presenting to Etlik City Hospital ED * Patients with hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma) * Patients with missing clinical or laboratory data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Emergencies metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer Emergency department admission Metastatic solid tumors Mortality Oncology

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.